Shares in Nanaimo-based marijuana company Tilray Inc. leaped nearly 20 per cent in early trading on Wednesday, then slipped back a bit, as investors respond enthusiastically to Tilray’s announcement about a medical cannabis export to the U-S. The gains come on the heels of a 30 per cent hike in value yesterday after word that Tilray has received approval to export a medical marijuana product south of the border, for use in a clinical trial. The product, a capsule containing two active ingredients from the cannabis plant, is being examined as a potential treatment for essential tremor — an involuntary shaking, often of the hands, during simple tasks such as eating or tying shoes. When Tilray completed its initial public offering in July, a single share was priced at 17-dollars, but they were trading at nearly 194-dollars U-S per share by mid-morning, slightly under the early morning surge of 230-dollars per share.